{
  "Variants Include": [
    {
      "Gene": "ATP2B1",
      "variants": [
        {
          "HGVS": "NM_001117799.2:c.2963A>G",
          "cDNA Change": {
            "transcript": "NM_001117799.2",
            "ref": "A",
            "alt": "G",
            "position": "2963"
          },
          "Protein Change": {
            "ref": "I",
            "alt": "V",
            "position": "988"
          },
          "Description in input context": "This substitution is predicted to affect kinase activity."
        },
        {
          "HGVS": "NM_001117799.2:c.3169C>T",
          "cDNA Change": {
            "transcript": "NM_001117799.2",
            "ref": "C",
            "alt": "T",
            "position": "3169"
          },
          "Protein Change": {
            "ref": "L",
            "alt": "L",
            "position": "1057"
          },
          "Description in input context": "This variant is located in a conserved region critical for calcium binding."
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Limb-Girdle Muscular Dystrophy Type 1A (LGMD1A)",
    "MONDO": "MONDO:0007429"
  },
  "Experiment Method": [
    {
      "Assay Method": "In vitro Kinase Assay",
      "Material used": {
        "Material Source": "Recombinant Protein",
        "Material Name": "Recombinant Human ATP2B1 Protein",
        "Description": "Recombinant human ATP2B1 protein was expressed and purified as previously described."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_001117799.2:c.2963A>G",
          "Conclusion": "Abnormal",
          "Molecular Effect": "reduced kinase activity",
          "Result Description": "The c.2963A>G variant exhibited a 40% reduction in kinase activity compared to wild-type ATP2B1."
        },
        {
          "Variant": "NM_001117799.2:c.3169C>T",
          "Conclusion": "Normal",
          "Molecular Effect": "No effect",
          "Result Description": "The c.3169C>T variant showed kinase activity comparable to wild-type ATP2B1."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Each condition was tested in triplicate with cells from 3 different donors."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Each assay was performed in duplicate."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type ATP2B1 protein was used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "A kinase inhibitor was used as a negative control."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "No",
        "Counts": "0"
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "No",
        "Counts": "0"
      },
      "Statistical analysis method": {
        "Statistical analysis method": "One-way ANOVA followed by Tukey's post-hoc test was used for statistical analysis."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Kinase activity between 70% and 130% of wild-type control.",
        "Source": "Literature"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Kinase activity less than 70% or greater than 130% of wild-type control.",
        "Source": "Literature"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}